Skip to main content
SpringerLink
Log in
Book cover

Hepatitis C Virus and Liver Transplantation pp 45–63Cite as

Treatment of Hepatitis C After Liver Transplantation

  • Chapter
  • First Online:

  • 1015 Accesses

Abstract

The goal of hepatitis C virus (HCV) treatment in liver transplant (LT) recipients is to prevent graft loss and liver-related complications. Currently, the primary approach to the management of transplant recipients with HCV has been to treat after transplantation (Table 4.1). Antiviral therapy can be undertaken early, within the first 6 months post-LT, when recurrent viremia is documented, but prior to the presence of histologic criteria for treatment. This is often termed preemptive therapy. More commonly, treatment with antiviral therapy is reserved for those with recurrent and progressive histologic disease. Experts recommend treatment for patients with moderate to severe necroinflammatory activity or mild to moderate fibrosis (F2 or greater). Peginterferon and ribavirin has been the mainstay of posttransplant therapy for the past 15 years. With the recent approval of the first direct-acting antiviral (DAA) drugs—NS3/4A protease inhibitors—the standard of care for patients with genotype 1 HCV infection has changed to a triple drug regimen of peg-IFN, RBV, and either telaprevir or boceprevir. Since the majority of transplant recipients with HCV are infected with HCV genotype 1, this offers a significant opportunity to improve outcomes in these patients. Although, triple therapy is not approved for use in transplant recipients, off-label use is occurring due to significant need for more efficacious therapies in patients with progressive or severe recurrent disease. However, significant challenges including a higher risk of adverse events and more drug–drug interactions have been identified in early reports. In the future, DAA drugs with improved tolerability and less drug–drug interactions may allow greater ease of use, better tolerability, and higher rates of viral clearance.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl. 2003;9:S95–100.

    Article  PubMed  Google Scholar 

  2. Wiesner R, Sorrell M, Villamil F, International Liver Transplantation Society Expert P. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1–9.

    Google Scholar 

  3. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004;78:1308–11.

    Article  PubMed  CAS  Google Scholar 

  4. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005;5:118–24.

    Article  PubMed  Google Scholar 

  5. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011;17:528–38.

    Article  PubMed  Google Scholar 

  6. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–98.

    Article  PubMed  CAS  Google Scholar 

  7. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008;15:699–709.

    Article  PubMed  CAS  Google Scholar 

  8. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274–87.

    Article  PubMed  CAS  Google Scholar 

  9. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–99.

    Article  PubMed  CAS  Google Scholar 

  10. Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55:322–7.

    Article  PubMed  CAS  Google Scholar 

  11. Duarte-Rojo A, Veldt BJ, Goldstein DD, et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012;94:197–203.

    Article  PubMed  CAS  Google Scholar 

  12. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577–85, 85 e1–3.

    Article  PubMed  CAS  Google Scholar 

  13. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant. 2011;11:1051–7.

    Article  PubMed  CAS  Google Scholar 

  14. Kawaoka T, Takahashi S, Takaki S, et al. IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepat. 2012 Sep;27:1467–72.

    Article  CAS  Google Scholar 

  15. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose Peg-interferon and ribavirin. Am J Transplant. 2006;6:2348.

    Article  PubMed  CAS  Google Scholar 

  16. Gordon FD, Kwo P, Ghalib R, et al. Peginterferon-alpha-2b and Ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol. 2012;46:700–8.

    Article  PubMed  CAS  Google Scholar 

  17. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766–77.

    Article  PubMed  Google Scholar 

  18. Selzner N, Renner E, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214–21.

    Article  PubMed  CAS  Google Scholar 

  19. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679–87.

    Article  PubMed  CAS  Google Scholar 

  20. Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8:2426–33.

    Article  PubMed  CAS  Google Scholar 

  21. Berenguer M, Prieto M, Palau A, et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol. 2004;16:1207–12.

    Article  PubMed  CAS  Google Scholar 

  22. Bizollon T, Pradat P, Mabrut JY, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant. 2007;7:448–53.

    Article  PubMed  CAS  Google Scholar 

  23. Gurusamy K, Tsochatzis E, Xirouchakis E, Burroughs A, Davidson B. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006803.

    Google Scholar 

  24. Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol. 2012;56:1310–6.

    Article  PubMed  CAS  Google Scholar 

  25. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132–9.e1.

    Article  PubMed  CAS  Google Scholar 

  26. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159–65.

    Article  PubMed  Google Scholar 

  27. Bertuzzo VR, Cescon M, Morelli MC, et al. Long-term antiviral treatment for recurrent hepatitis C after liver transplantation. Dig Liver Dis. 2012;44:861–67.

    Article  PubMed  Google Scholar 

  28. Calmus Y, Duvoux C, Pageaux G, et al. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNalpha-2a plus ribavirin. J Hepatol. 2012;57:564–71.

    Article  PubMed  CAS  Google Scholar 

  29. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    Article  PubMed  CAS  Google Scholar 

  30. Zeuzem S, Andreone P, Pol S, Laawitz E, Diego M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.

    Article  PubMed  CAS  Google Scholar 

  31. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;264:1207–17.

    Article  Google Scholar 

  32. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364:1195–206.

    Article  PubMed  CAS  Google Scholar 

  33. Hezode C, Dorival C, Zoulim F, Larrey DG, Pol S, Cacoub P, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin in 455 cirrhotic nonresponders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology. 2012;56(Suppl):51.

    Google Scholar 

  34. Verna EC, Terry N, Lukose T, Mentore K, Olsen SK, et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV-infected patients awaiting liver transplantation. Hepatology. 2012;56(Suppl):A52.

    Google Scholar 

  35. Garg V, Heeswijk R van, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20–7.

    Article  PubMed  CAS  Google Scholar 

  36. Hulskotte E, Gupta S, Xuan F, Zutven M van, O’Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622–30.

    Article  PubMed  CAS  Google Scholar 

  37. Burton JR Jr, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety and tolerability. Am J Transpl. 2012;12 Suppl 3:LB01.

    Google Scholar 

  38. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al. Short report: telaprevir-based triple therapy in liver transplanted HCV patients: a 112 week pilot study providing safety and efficacy. Liver Transpl. 2012;18:1464–70.

    Article  PubMed  Google Scholar 

  39. Coilly A, Roche T, Antonini T, Samuel D, Duclos-Vallee J. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation; a first multicentric experience. Hepatology. 2012;56(Suppl):9.

    Google Scholar 

  40. Pungpapong S, Murphy JL, Henry TM, Ryland K, Satyanarayana R, Rosser B, et al. Preliminary experience using telaprevir with peginterferon and ribavirin for treatment of HCV genotype 1 after liver transplantation. Hepatology. 2012;56(Suppl):10.

    Google Scholar 

  41. Aqel B, Carey EJ, Byrne TJ, Rakela J, Vargas HE. Multicenter preliminary experience utilizing boceprevir with pegylated interferon and ribavirin for treatment of recurrent hepatitis C genotype 1 after liver transplantation. Hepatology. 2012;56(Suppl):706.

    Google Scholar 

  42. O’Leary JG, McKenna GJ, Klintmalm G, Davis GL. 100 % cEVR post-liver transplant with telaprevir triple drug therapy. Hepatology. 2012;56(Suppl):707.

    Google Scholar 

  43. Mantry PS, Wu C, Weinstein JS, Mubarak A, Nazario HE, Madani B, et al. Early and end of treatment virologic responses in patients with hepatitis C genotype 1 recurrence after liver transplant treated with triple therapy using telaprevir: a single center experience. Hepatology. 2012;56(Suppl):712.

    Google Scholar 

  44. Nair S, Waters B. Telaprevir can be used effectively and saffetly to treat recurrent HCV in liver transplant recipients receiving tacrolimus based immunosuppression. Hepatology. 2012;56(Suppl):720.

    Google Scholar 

  45. Burton JR Jr, O’Leary JG, Verna EC, Lai JC, Everson GT, Trotter JF, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group. Hepatology. 2012;56(Suppl):211.

    Google Scholar 

  46. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial. Hepatology. 2013;57(3):974–84.

    Article  PubMed  CAS  Google Scholar 

  47. Sulkowski MS, Robers S, Afdhal N, Andreone P, Diago M, Pols S, et al. Ribavirin dose modification in treatment naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]. J Hepatol. 2012;56 Suppl 2:S459–60.

    Article  Google Scholar 

  48. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. A case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C following liver retransplantation. Liver Transpl. 2012;18:1053–9.

    Article  PubMed  Google Scholar 

  49. Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-C1: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (p/R) in treatment-naive patients with chronic genotype 1 HCV infection. Paper presented at 46th Annual Meeting of the European Association for the Study of the Liver, March 30–April 3, 2011; Berlin, Germany.

    Google Scholar 

  50. Fried MW, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: final analysis of the pillar phase IIb study. Paper presented at 62nd Annual Meeting of the American Assocation for the Study of Liver Diseases, November 4–8, 2011; San Francisco, CA.

    Google Scholar 

  51. Hezode C, Hirschfield G, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Paper presented at 62nd Annual Meeting of the American Association for the Study of Liver Diseases, November 4–8, 2011; San Francisco, CA.

    Google Scholar 

  52. Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naive patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study [abstract 230]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  53. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves svr12 rates (observed data) of 99 % in treatment-naive patients and 93 % in prior null responders with HCV genotype 1 infection [abstract LB1]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  54. Sulkowski MS, Gardiner D, Rodriguez-Torres M, et al. All-oral combination of DCV + SOF ± RBV in treatment-naive patients with HCV GT 1, 2 or 3 [abstract LB2]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  55. Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94 % in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection [abstract LB3]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  56. Lok AS, Gardiner D, Hezode C, et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) [abstract 79]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  57. Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100 % SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB), and ribavirin ® +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract 81]. Paper presented at 63rd Annual Meeting of the American Assocation for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  58. Thompson AJ, Shiffman ML, Rossaro L, et al. Six weeks of a NS5A inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon/ribavirin (PR) achieves high SVR rates in genotype 1 IL28B CC treatment naive HCV patients: interim results of a prospective, randomized trial [abstract 759]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  59. Kiser J, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 Jul 2. 401: 10.1038/nrgastro.2013.106

    Google Scholar 

  60. Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013;17:73–91.

    Article  PubMed  Google Scholar 

  61. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822–32.

    Article  PubMed  CAS  Google Scholar 

  62. Sekar V, Verloes R, Meyvisch P, Spittaels K, Akuma SH, De Smedt G. TMC435 and drug interactions: evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. Paper presented at 45th European Assocation for the Study of the Liver, April 14–18, 2010; Vienna, Austria.

    Google Scholar 

  63. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Paper presented at 61st Annual Meeting of the American Association for the Study of Liver Diseases, October 30-November 3, 2010; Boston, MA.

    Google Scholar 

  64. Ouwerkerk-Mahadevan S, Simion A, Mortier S, Peeters M, Beumont-Mauviel M. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus [abstract 80]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  65. Sabo JP, Kashuba ADM, Ballow CH, et al. Cytochrome P450 (CYP) interactions with the HCV protease inhibitor faldaprevir (BI 201335) in healthy volunteers [abstract A-1248]. Paper presented at The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9–12, 2012; San Francisco, CA.

    Google Scholar 

  66. Sane R, Podila L, Mathur A, et al. Mechanism of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI 201335. Paper presented at 46th Annual Meeting of the European Association for the Study of the Liver, March 30–April 20, 2011; Berlin, Germany.

    Google Scholar 

  67. Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis. Aug. 2011;15(3):627–39.

    Google Scholar 

  68. Bifano M, Sevinsky H, Persson A, et al. Daclatasvir has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects. Paper presented at American Association for the Study of Liver Diseases, November 5–8, 2011; San Francisco, CA.

    Google Scholar 

  69. Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. Paper presented at 47th Annual Meeting of the European Association for the Study of the Liver April 18–22, 2012; Barcelona, Spain.

    Google Scholar 

  70. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds W. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers [abstract 1869]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.

    Google Scholar 

  71. Lok AS, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.

    Article  PubMed  CAS  Google Scholar 

  72. Chayama K, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742–8.

    Article  PubMed  CAS  Google Scholar 

  73. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds W, Hindes RG. Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.

    Article  PubMed  CAS  Google Scholar 

  74. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsecki T, Sigglekow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology and Hepatology Division, Department of Medicine, University of Colorado Denver, 1635 Aurora Court, B-154, 80045, Aurora, CO, USA

    James R. Burton Jr. MD & Gregory T. Everson MD

  2. Gastroenterology Department, University of California San Francisco, 513 Parnassus, S-357, 94143-0538, San Francisco, CA, USA

    Norah A. Terrault MD, MPH

  3. Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, 12850 E. Montview Blvd. V20-4102, Mail Stop C238, 80045, Aurora, CO, USA

    Jennifer J. Kiser PharmD

Authors
  1. James R. Burton Jr. MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norah A. Terrault MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer J. Kiser PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory T. Everson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory T. Everson MD .

Editor information

Editors and Affiliations

  1. La Fe Hospital, University of Valencia and Ciberehd, Valencia, Spain

    Marina Berenguer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Burton, J., Terrault, N., Kiser, J., Everson, G. (2014). Treatment of Hepatitis C After Liver Transplantation. In: Berenguer, M. (eds) Hepatitis C Virus and Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8438-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8438-7_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8437-0

  • Online ISBN: 978-1-4614-8438-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation